뒤로
AIxCrypto Holdings, Inc.(QLGN) 가격
QLGN 주가 차트
QLGN 수입
AIxCrypto Holdings, Inc.
$1.42
3.64%
$0.04
종가: Feb 06, 16:00:00 GMT-5
$1.42
0%
$0
애프터마켓: Feb 06, 20:00:00 GMT-5
아직 데이터 없음Earnings FAQ
QLGN의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
AIxCrypto Holdings, Inc. QLGN의 지난 분기 매출 실적은 어땠나요?
AIxCrypto Holdings, Inc.의 매출 추정치는 얼마인가요?
AIxCrypto Holdings, Inc.의 수익 품질 점수는 얼마인가요?
AIxCrypto Holdings, Inc.는 언제 수익을 보고하나요?
AIxCrypto Holdings, Inc.의 예상 수익은 얼마인가요?
AIxCrypto Holdings, Inc.은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$1.37
시가
$1.37
일일 범위
$1.36 - $1.49
52주 범위
$1.42 - $8.81
거래량
--
평균 거래량
2.6M
EPS(TTM)
2.85
배당수익률
--
시가총액
$2.8M
Qualigen Therapeutics, Inc.란 무엇인가요?
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Carlsbad, California. The company went IPO on 2015-06-24. The firm is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.